State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
J Med Chem. 2022 Sep 22;65(18):12176-12187. doi: 10.1021/acs.jmedchem.2c00855. Epub 2022 Sep 6.
Targeted degradation of proteins, especially those regarded as undruggable or difficult to drug, attracts wide attention to develop novel therapeutic strategies. Glutathione peroxidase 4 (GPX4), the key enzyme regulating ferroptosis, is currently a target with just covalent inhibitors. Here, we developed a targeted photolysis approach and achieved efficient degradation of GPX4. The photodegradation-targeting chimeras (PDTACs) were synthesized by conjugating a clinically approved photosensitizer (verteporfin) to noninhibitory GPX4-targeting peptides. These chimeras selectively degraded the target protein in both cell lysates and living cells upon red-light irradiation. The targeted photolysis of GPX4 resulted in dominant ferroptotic cell death in malignant cancer cells. Moreover, the dying cells resulting from the PDTACs exhibited potent immunogenicity in vitro and efficiently elicited antitumor immunity in vivo. Our approach therefore provides a novel method to induce GPX4 dysfunction based on noncovalent binding and specifically trigger immunogenic ferroptosis, which may boost the application of ferroptosis in cancer immunotherapy.
靶向蛋白质降解,特别是针对那些被认为不可成药或难以成药的蛋白质,为开发新的治疗策略吸引了广泛关注。谷胱甘肽过氧化物酶 4(GPX4)是调节铁死亡的关键酶,目前是唯一具有共价抑制剂的靶标。在这里,我们开发了一种靶向光解方法,实现了 GPX4 的高效降解。光降解靶向嵌合体(PDTAC)是通过将临床批准的光敏剂(维替泊芬)与非抑制性 GPX4 靶向肽缀合而合成的。这些嵌合体在红光照射下可在细胞裂解物和活细胞中选择性地降解靶蛋白。GPX4 的靶向光解导致恶性癌细胞中占主导地位的铁死亡细胞死亡。此外,PDTACs 诱导的死亡细胞在体外具有很强的免疫原性,并在体内有效地引发抗肿瘤免疫。因此,我们的方法提供了一种基于非共价结合的诱导 GPX4 功能障碍的新方法,并特异性触发免疫原性铁死亡,这可能会促进铁死亡在癌症免疫治疗中的应用。